<unk>  is indicated to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer.
Trilaciclib
Atoltivimab
Sotrovimab
Nirsevimab
Regdanvimab
Odesivimab
Maftivimab
Obiltoxaximab